MedTrace Logo

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

NCT01247194 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-02-03

No results posted yet for this study

Summary

The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.

Conditions

  • Chronic Genotype 1 Hepatitis C Virus Infection

Interventions

DRUG

PPI-461

capsule, oral, once daily for 3 days

DRUG

Placebo

capsules, oral, once daily for 3 days

Sponsors & Collaborators

  • Presidio Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Nathaniel Brown, M.D. · Presidio Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-05-31
Completion
2011-06-30

Countries

  • United States
  • Denmark
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01247194 on ClinicalTrials.gov